Exploring novel therapeutics targets for psoriasis: Insights into pathogenesis and drug development
Keywords:
Therapeutic, Psoriasis, PathogenesisAbstract
Objective This research aimed to explore and identify novel therapeutic targets for psoriasis, elucidate the underlying pathogenic mechanisms, and develop innovative drug candidates or repurpose existing drugs for effective treatment. Methods A comprehensive literature review was conducted to gather current knowledge on psoriasis pathogenesis and existing treatment modalities. Various molecular targets involved in key cellular processes, signaling pathways, and immune dysregulation were identified and evaluated as potential therapeutic targets. In vitro experiments using human skin cell cultures and animal models were employed to assess the efficacy, safety, and mechanism of action of developed drug candidates or repurposed drugs. Pharmacological evaluations, including bioavailability and pharmacokinetic studies, were performed to determine their potential for clinical translation. Results The study identified several promising therapeutic targets implicated in the pathogenesis of psoriasis, including specific cytokines, immune cell subsets, and signaling pathways. Experimental findings demonstrated the efficacy of newly developed drug candidates or repurposed drugs in suppressing keratinocyte hyper proliferation, mitigating inflammation, and modulating immune responses. Pharmacological evaluations indicated favorable drug properties, including suitable bioavailability and pharmacokinetic profiles. Conclusion The research findings provide valuable insights into the pathogenesis of psoriasis and potential therapeutic targets for intervention. The identification and development of novel drug candidates or repurposing existing drugs targeting these therapeutic targets hold promise for improved treatment outcomes in psoriasis patients. Further translational research and clinical trials are warranted to validate these findings and establish their clinical efficacy and safety. The interdisciplinary approach merging pharmacology and dermatology in this study showcases the importance of collaboration and highlights the potential for developing personalized treatment strategies for psoriasis patients.References
Rachakonda, T. D., Schupp, C. W., Armstrong, A. W., & Psoriasis Meta-analysis Network. (2014). Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 70(3), 512-516.
Gelfand, J. M., Feldman, S. R., Stern, R. S., Thomas, J., Rolstad, T., Margolis, D. J. (2005). Determinants of quality of life in patients with psoriasis: A study from the US population. Journal of the American Academy of Dermatology, 53(4), 573-578. doi: 10.1016/j.jaad.2005.04.064
Gottlieb, A. B., Chao, C., Dann, F., Gilleaudeau, P., Wang, A., Chen, D. M., Krueger, G. G. (2005). Psoriasis comorbidities. Journal of Dermatological Treatment, 16(5-6), 319-323. doi: 10.1080/09546630500328045
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014). Immunology of psoriasis. Annual Review of Immunology, 32, 227-255.
Tsoi, L. C., Spain, S. L., Knight, J., Ellinghaus, E., Stuart, P. E., Capon, F., & Barker, J. N. (2012). Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 44(12), 1341-1348.
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009). Psoriasis. New England Journal of Medicine, 361(5), 496-509.
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., & Gelfand, J. M. (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 80(4), 1029-1072.
Gudjonsson, J. E., Karason, A., Runarsdottir, E. H., Antonsdottir, A. A., Hauksson, V. B., & Jonsson, H. H. (2007). Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients--An analysis of 1019 HLA-C- and HLA-B-typed patients. Journal of Investigative Dermatology, 127(7), 1830-1832. doi: 10.1038/sj.jid.5700807
Gordon, K. B., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y. K., & Li, Q. (2018). Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo and active comparator-controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology, 78(5), 863-871. doi: 10.1016/j.jaad.2017.12.016
Gelfand, J. M., Weinstein, R., Porter, S. B., Neimann, A. L., Berlin, J. A., & Margolis, D. J. (2005). Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Archives of Dermatology, 141(12), 1537-1541.
Gudjonsson, J. E., Elder, J. T., & Goldsmith, L. A. (2007). Introduction to the biology of psoriasis. In Fitzpatrick's dermatology in general medicine (8th ed., Vol. 1, pp. 169-177). McGraw-Hill.
Gordon, K. B., Feldman, S. R., Koo, J. Y., Menter, A., Rolstad, T., & Krueger, G. (2018). Definitions of treatment response in psoriasis: An FDA perspective. Journal of the American Academy of Dermatology, 79(2), 314-321.
Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y., & National Psoriasis Foundation. (2005). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. Journal of the American Academy of Dermatology, 52(3), 494-505.
